Drug interactions
Medroxyprogesterone + Tucatinib
Severity: Moderate
Medroxyprogesterone and Tucatinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Tucatinib is a moderate CYP3A inhibitor and may raise medroxyprogesterone exposure. The effect is likely modest, with possible increased progestin adverse effects.
What this interaction means in plain words
Medroxyprogesterone and Tucatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Medroxyprogesterone belongs to Endocrine; Tucatinib belongs to Oncology.
Why it happens
Tucatinib inhibits CYP3A4, reducing medroxyprogesterone clearance.
What to do
Monitor for progestin adverse effects and reduce the dose if they occur.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Medroxyprogesterone and Tucatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Medroxyprogesterone
Other interactions of Tucatinib
- Cisapride + Tucatinib Contraindicated
- Eletriptan + Tucatinib Contraindicated
- Ergotamine + Tucatinib Contraindicated
- Flibanserin + Tucatinib Contraindicated
- Ranolazine + Tucatinib Contraindicated
- Amobarbital + Tucatinib Major
Frequently asked questions
Can I take Medroxyprogesterone with Tucatinib?
MediHelp rates the interaction as moderate. Medroxyprogesterone and Tucatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Tucatinib is a moderate CYP3A inhibitor and may raise medroxyprogesterone exposure. The effect is likely modest, with possible increased progestin adverse effects.
How serious is the interaction between Medroxyprogesterone and Tucatinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for progestin adverse effects and reduce the dose if they occur.
What other medicines interact with Medroxyprogesterone?
MediHelp also lists interactions of Medroxyprogesterone with, for example, Bosentan, Brigatinib, Eslicarbazepine. The full list is on the Medroxyprogesterone page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
